STATs signaling pathways in dendritic cells: As potential therapeutic targets?

• Published in: International reviews of immunology Vol. 43; no. 3; p. 138
• Main Authors: Sohrabi, Sepideh, Masoumi, Javad, Naseri, Bahar, Ghorbaninezhad, Farid, Alipour, Shiva, Kazemi, Tohid, Ahmadian Heris, Javad, Aghebati Maleki, Leili, Basirjafar, Pedram, Zandvakili, Raziyeh, Doustvandi, Mohammad Amin, Baradaran, Behzad
• Format: Journal Article
• Language: English
• Published: England 03.05.2024
• Subjects: Animals; Antigen Presentation - immunology; Autoimmune Diseases - immunology; Autoimmune Diseases - metabolism; Autoimmune Diseases - therapy; Cell Differentiation - immunology; Dendritic Cells - immunology; Dendritic Cells - metabolism; Humans; Immunotherapy - methods; Molecular Targeted Therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; Signal Transduction - immunology; STAT Transcription Factors - metabolism; Autoimmune disease; cancer; JAK/STAT signaling; T cell; dendritic cell
• ISSN: 1563-5244
• DOI: 10.1080/08830185.2023.2274576

Dendritic cells (DCs) are professional antigen-presenting cells (APCs), including heterogenous populations with phenotypic and functional diversity that coordinate bridging innate and adaptive immunity. Signal transducer and activator of transcriptions (STAT) factors as key proteins in cytokine signaling were shown to play distinct roles in the maturation and antigen presentation of DCs and play a pivotal role in modulating immune responses mediated by DCs such as differentiation of T cells to T helper (Th) 1, Th2 or regulatory T (Treg) cells. This review sheds light on the importance of STAT transcription factors' signaling pathways in different subtypes of DCs and highlights their targeting potential usages for improving DC-based immunotherapies for patients who suffer from cancer or diverse autoimmune conditions according to the type of the STAT transcription factor and its specific activating or inhibitory agent.